Genital Warts Clinical Trial
Official title:
Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Small Genital Warts:a Randomized, Open-label Trial
NCT number | NCT03948321 |
Other study ID # | 2019-09 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 10, 2019 |
Est. completion date | December 30, 2019 |
This study is being done to compare a new, continuous illumination and short Incubation time regimen of aminolevulinic acid photodynamic therapy(ALA-PDT) to a conventional regimen for treatment of small genital warts. The hypothesis is that the continuous illumination approach will be less or even no painful, but equally efficacious, as the old regimen.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 30, 2019 |
Est. primary completion date | December 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Clinical diagnosed with Genital Warts; 2. Aged > 18 years; 3. All patients are unfit and reluctant to undergo surgery for any reasons, and volunteered to participate in the study and ability to understand and the willingness to sign a written informed consent. Patents agreed to take a picture of the skin lesions. 4. The maximum diameter of a single carcass does not exceed 0.5cm; the skin lesions are at least 6 or more or substantially symmetric Exclusion Criteria: 1. Those who did not complete the informed consent; 2. The lesions belongs to any of the following conditions: There is damage and inflammation, which may lead to the drug entering the open wound; the individual corpus callosum is more than 0.5cm in diameter; the corpus callosum is located in the vagina, the anal canal, the cervix; 3. Patients with skin photoallergic diseases, porphyria; 4. Known to have a history of allergies to test drugs (porphyrins) and their chemically similar drugs; 5. Patients with other obvious diseases that may affect the evaluation of efficacy; (6)Scars or patients with a tendency to form scars; (7)Known to have severe immune dysfunction, or long-term use of glucocorticoids and immunosuppressants; (8)Severe heart, liver, kidney disease; with hereditary or acquired People with sexual coagulopathy; (9)Those with severe neurological, psychiatric or endocrine diseases; (10)Women who are pregnant, breast-feeding or using inappropriate contraceptives; those with a history of drug abuse; those who have participated in other drug clinical trials within 4 weeks before treatment. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Dermatology Hospital | Shanghai | Shanghai, Jingan, China |
Lead Sponsor | Collaborator |
---|---|
Shanghai Dermatology Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The clearance rate of Genital Warts | The clearance rate of Genital Warts will be measured at one week after the last treatment. | one week after the last treatment | |
Secondary | Pain assessment | The pain will be assessed using Visual Analogue Scale(VAS) with a score range of 0-10. The higher the score, the greater the pain, with 0 being no pain and 10 being the most unbearable pain. Pain will be measured at different time points during and after every treatment ,including immediately, 1st min, 3rd min, 5th min, 7th min, 10th min , and every 10 min to the end of treatment and 2nd h, 12th h, 24th h and 48th h after treatment. | Immediately, 1st minute, 3rd minute, 5th minute, 7th minute, 10th minute , and every 10 minute to the end of treatment and 2 hours, 12 hours, 24hours and 48 hours after treatment | |
Secondary | The recurrence rates after treatment | The recurrence rates will be measured at 3 months after the last treatment. | 3 months after the last treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Completed |
NCT03158220 -
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
|
Phase 3 | |
Completed |
NCT01651949 -
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
|
Phase 3 | |
Completed |
NCT00520598 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
|
Phase 2 | |
Completed |
NCT00551187 -
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
|
Phase 2 | |
Terminated |
NCT01468636 -
A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
|
Phase 4 | |
Recruiting |
NCT03296397 -
Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response
|
Phase 3 | |
Active, not recruiting |
NCT05314023 -
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
|
Phase 3 | |
Completed |
NCT00674739 -
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
|
Phase 3 | |
Completed |
NCT00862810 -
Alternate Dosing Schedules Study for HPV Vaccine
|
Phase 4 | |
Completed |
NCT02280642 -
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
|
Phase 4 | |
Completed |
NCT00092482 -
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
|
Phase 3 | |
Completed |
NCT02188004 -
The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases
|
||
Completed |
NCT01553994 -
Effectiveness Study of Gardasil on Condyloma
|
N/A | |
Completed |
NCT00189293 -
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
|
Phase 4 | |
Active, not recruiting |
NCT00092534 -
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
|
Phase 3 | |
Completed |
NCT02462187 -
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
|
Phase 2 | |
Completed |
NCT00501137 -
A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine
|
Phase 3 | |
Active, not recruiting |
NCT02750202 -
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
|
Phase 3 | |
Active, not recruiting |
NCT02653118 -
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
|